Symptomatic metastatic brain or meningeal tumors
Symptomatic metastatic brain or meningeal tumors
Symptomatic metastatic brain or meningeal tumors
Symptomatic metastatic brain or meningeal tumors, neuroblastoma (NB); if a patient does not have known or symptomatic central nervous system (CNS) metastases at screening, then brain imaging is not required for the purpose of this trial
Symptomatic metastatic brain or meningeal tumors
Symptomatic metastatic brain or meningeal tumors
Symptomatic metastatic brain or meningeal tumors
Known history of metastatic brain or meningeal tumors.
Symptomatic metastatic brain or meningeal tumors
Symptomatic brain or meningeal tumors.
Symptomatic metastatic brain or meningeal tumors
Symptomatic metastatic brain or leptomeningeal tumors (asymptomatic or treated metastatic brain or leptomeningeal tumors are allowed)
Symptomatic meningeal or parenchymal brain lymphoma
Symptomatic metastatic brain or meningeal tumors
Symptomatic metastatic brain or meningeal tumors; treated and stable, asymptomatic brain metastases, as long as treatment was greater than 4 weeks prior to informed consent, are allowed
Symptomatic metastatic brain or meningeal tumors
Symptomatic metastatic brain or meningeal tumors (asymptomatic or treated metastatic brain and leptomeningeal tumors are allowed)
Symptomatic metastatic brain or leptomeningeal tumors (asymptomatic or treated metastatic brain or leptomeningeal tumors are allowed)
Metastatic brain or meningeal tumors (symptomatic or asymptomatic).
History of symptomatic metastatic brain or meningeal tumors unless the subject is longer than 3 months from the end of definitive therapy before the first dose of the investigational drug and has clinically or radiologically no evidence of tumor growth.
Symptomatic metastatic brain or meningeal tumors
Symptomatic metastatic brain or meningeal tumors
Symptomatic metastatic brain or meningeal tumors; baseline brain imaging is not required
Metastatic brain or meningeal tumors
Known metastatic brain or meningeal tumors, unless the subject is >3 months from definitive therapy and clinically stable (supportive therapy with steroids or anticonvulsant medications is allowed) with respect to the tumor at the time of the first dose of study drug
Symptomatic metastatic brain or meningeal tumors
History of symptomatic metastatic brain or meningeal tumors unless the subject is >3 months from the end of definitive therapy before the first dose of study drug and has clinically or radiologically no evidence of tumor growth.
Evidence of significant central nervous system disease including seizure disorder requiring medication, symptomatic metastatic brain or meningeal tumors
Symptomatic metastatic brain or meningeal tumors
